Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Sponsor
The Affiliated Hospital Of Guizhou Medical University
Study ID
NCT06833112
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.
  • Adalimumab — DRUG
    The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.

Study Details

The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.

Key Dates

Start date
Feb 28, 2025
Status verified
Jan 2025
Primary completion
Aug 31, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    The subjects were treated with adalimumab (HS016) in combination with secukinumab

Primary Outcome Measure

Assessment of SpondyloArthritis International Society 40 (ASAS 40) [ Time Frame: week 52 ]

Central Contacts

Related Studies